Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Arformoterol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 known ✓ | P07550 | 11/20 | 0.98 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.98 |
| ▸ | ADRB3 | P13945 | 4/20 | 0.98 |
| ▸ | DRD2 | P14416 | 2/20 | 0.98 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.98 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.98 |
| ▸ | TSHR | P16473 | 2/20 | 0.98 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.60 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Arformoterol SCHEMBL30969874 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL15856256 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL349579 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL117865 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Formoterol SCHEMBL6528975 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL4247 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL458736 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL6547706 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL3679114 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 | |
| Arformoterol SCHEMBL30154976 | 0.99 | ADRB2 (1.00) | ADRB2ADRB1ADRB3DRD2CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2104490-B2 | MICRONISED PARTICLES OF LOW-DOSAGE STRENGTH ACTIVE AGENTS FOR POWDER FORMULATIONS FOR INHALATION | CHIESI FARM SPA (IT) | 2024-06-26 | — | — | EP | claimed |
| EP-3569222-B1 | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2024-06-26 | — | — | EP | claimed |
| EP-2881108-B1 | Improved medicinal aerosol formulations | JAGOTEC AG (CH) | 2023-12-27 | — | — | EP | claimed |
| EP-3527199-B1 | DRY POWDER FORMULATION COMPRISING A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2022-09-07 | — | — | EP | claimed |
| EP-3515439-B1 | PHARMACEUTICAL COMPOSITION COMPRISING TIOTROPIUM BROMIDE | MEXICHEM FLUOR SA DE CV (MX) | 2021-12-15 | — | — | EP | claimed |
| EP-3620176-B1 | A PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC | CHIESI FARM SPA (IT) | 2021-08-11 | — | — | EP | claimed |
| EP-3689379-B1 | A PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC | CHIESI FARM SPA (IT) | 2021-08-11 | — | — | EP | claimed |
| EP-3628331-B1 | A PROCESS FOR PREPARING A DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC | CHIESI FARM SPA (IT) | 2021-08-11 | — | — | EP | claimed |
| EP-3556347-B1 | PHARMACEUTICAL COMPOSITION | MEXICHEM FLUOR SA DE CV (MX) | 2021-03-24 | — | — | EP | claimed |
| EP-3409270-B1 | DRY POWDER FORMULATION COMPRISING AN ANTICHOLINERGIC, A CORTICOSTEROID AND A BETA-ADRENERGIC FOR ADMINISTRATION BY INHALATION | CHIESI FARM SPA (IT) | 2021-02-24 | — | — | EP | claimed |
| EP-1158970-B1 | COMBINATIONS OF FORMOTEROL AND A TIOTROPIUM SALT | NOVARTIS AG (CH) | 2006-09-20 | — | — | EP | claimed |
| EP-1210943-B1 | New use for budesonide and formoterol | ASTRAZENECA AB (SE) | 2006-06-14 | — | — | EP | claimed |
| EP-1496917-B1 | COMBINATION OF A BETA-2 ADRENOCEPTOR AGONISTS AND AN AMINOSUGARS AND THEIR USE FOR THE TREATMENT IMMUNOMODULATORY DISORDERS | ASTION DEV AS (DK) | 2005-12-07 | — | — | EP | claimed |
| EP-1007017-B1 | NEW FORMULATION FOR INHALATION HAVING A POURED BULK DENSITY OF 0.28 TO 0.38 G/ML, A PROCESS FOR PREPARING THE FORMULATION AND THE USE THEREOF | ASTRAZENECA AB (SE) | 2005-02-02 | — | — | EP | claimed |
| EP-1133284-B1 | A PROCESS FOR THE PREPARATION OF CRYSTALLINE PARTICLES | ASTRAZENECA AB (SE) | 2004-10-06 | — | — | EP | claimed |
| EP-1152753-B1 | COMBINATIONS OF FORMOTEROL AND FLUTICASONE PROPIONATE FOR ASTHMA | NOVARTIS AG (CH) | 2004-05-12 | — | — | EP | claimed |
| EP-1156790-B1 | COMBINATIONS OF FORMOTEROL AND MOMETASONE FUROATE | NOVARTIS AG (CH) | 2003-06-04 | — | — | EP | claimed |
| EP-1014993-B1 | NEW USE FOR BUDESONIDE AND FORMOTEROL | ASTRAZENECA AB (SE) | 2002-08-14 | — | — | EP | claimed |
| EP-0613371-B1 | NEW COMBINATION OF FORMOTEROL AND BUDESONIDE | ASTRAZENECA AB (SE) | 2002-03-06 | — | — | EP | claimed |
| EP-0717616-B1 | PROCESS FOR CONDITIONING SUBSTANCES | ASTRAZENECA AB (SE) | 2001-03-21 | — | — | EP | claimed |